THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell ...

(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to ...

The long-acting monoclonal antibody is designed to provide "rapid and durable protection" through 5 months -- the typical ...

The collaboration will focus on advancing the potential drug candidate—formerly known as VIS513—through Phase III clinical ...

Serum Institute and DNDi sign MoU to develop and scale a dengue monoclonal antibody vaccine with Phase 3 trials in India, Brazil and other endemic countries ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Recent innovations across the multiple ADC components, such as enhanced antibody-targeting to the tumors, better linker ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.